{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:57:55Z","timestamp":1780390675553,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Extranodal nasal-type natural killer\/T-cell lymphoma (ENKTL) is an Epstein\u2013Barr virus (EBV) associated lymphoma that progresses rapidly and relapses frequently. Advanced ENKTL is multidrug chemoresistant and has a poor prognosis. In this study, we aim to develop a novel hexokinase domain component 1 (HKDC1)-based antitumor target for ENKTL that is involved with the antimetabolic signaling pathway, EBV replication, and P-glycoprotein (P-gp) expression. We showed that HKDC1 is highly upregulated in ENKTL cells and HKDC1 knockdown significantly suppresses ENKTL tumor growth. In addition, HKDC1 is highly identical with four other hexokinase isoforms, with the only difference being in the last eight amino acids (aa) at the C-terminal. Further investigation showed that peptide delivery of the last eight aa of HKDC1 at the C-terminal (HKC8) with D-configuration using transferrin (Tf) receptor internalization sequence (Tf-D-HKC8) inhibits HKDC1 association with vascular endothelial growth factor 1 (VDAC1), resulting in mitochondrial dysfunction and reactive oxygen species (ROS) overgeneration and subsequently suppressing EBV replication and P-gp expression, making it very effective in killing EBV-positive ENKTL cells. Further in vivo experiments showed that local injection of Tf-D-HKC8 peptide significantly suppresses ENKTL tumor growth and EBV replication in ENKTL xenograft mouse models. We conclude that HKDC1 C-terminal-based peptides inhibit ENKTL by modulation of mitochondrial function and EBV suppression.<\/jats:p>","DOI":"10.1038\/s41375-020-0801-5","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T13:03:23Z","timestamp":1584968603000},"page":"2736-2748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["HKDC1 C-terminal based peptides inhibit extranodal natural killer\/T-cell lymphoma by modulation of mitochondrial function and EBV suppression"],"prefix":"10.1038","volume":"34","author":[{"given":"Qi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-0779","authenticated-orcid":false,"given":"Paul","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"801_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03987-2","volume":"9","author":"O Dufva","year":"2018","unstructured":"Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018;9:1567.","journal-title":"Nat Commun"},{"key":"801_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11899-018-0430-5","volume":"13","author":"R Suzuki","year":"2018","unstructured":"Suzuki R. NK\/T cell lymphoma: updates in therapy. Curr Hematol Malig Rep. 2018;13:7\u201312.","journal-title":"Curr Hematol Malig Rep"},{"key":"801_CR3","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","volume":"126","author":"Y Yang","year":"2015","unstructured":"Yang Y, Zhu Y, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126:1424\u201332. quiz 1517.","journal-title":"Blood"},{"key":"801_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, et al. Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma. J Hematol Oncol. 2018;11:15.","journal-title":"J Hematol Oncol"},{"key":"801_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47:1061\u20136.","journal-title":"Nat Genet"},{"key":"801_CR6","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood. 2017;129:2437\u201342.","journal-title":"Blood"},{"key":"801_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3389\/fonc.2018.00679","volume":"8","author":"H Zhang","year":"2018","unstructured":"Zhang H, Lu J, Jiao Y, Chen Q, Li M, Wang Z, et al. Aspirin inhibits natural killer\/T-cell lymphoma by modulation of VEGF expression and mitochondrial function. Front Oncol. 2018;8:679.","journal-title":"Front Oncol"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-019-0716-7","volume":"12","author":"S de Mel","year":"2019","unstructured":"de Mel S, Hue SS, Jeyasekharan AD, Chng WJ, Ng SB. Molecular pathogenic pathways in extranodal NK\/T cell lymphoma. J Hematol Oncol. 2019;12:33.","journal-title":"J Hematol Oncol"},{"key":"801_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2174\/138920011798357006","volume":"12","author":"RA Darby","year":"2011","unstructured":"Darby RA, Callaghan R, McMahon RM. P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab. 2011;12:722\u201331.","journal-title":"Curr Drug Metab"},{"key":"801_CR10","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","volume":"76","author":"M Yamaguchi","year":"1995","unstructured":"Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351\u20136.","journal-title":"Cancer"},{"key":"801_CR11","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/cam4.494","volume":"4","author":"M Yoshimori","year":"2015","unstructured":"Yoshimori M, Takada H, Imadome K, Kurata M, Yamamoto K, Koyama T, et al. P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases. Cancer Med. 2015;4:1494\u2013504.","journal-title":"Cancer Med"},{"key":"801_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J Hematol Oncol. 2016;9:109.","journal-title":"J Hematol Oncol"},{"key":"801_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/hon.2207","volume":"34","author":"W Yong","year":"2016","unstructured":"Yong W. Clinical study of l-asparaginase in the treatment of extranodal NK\/T-cell lymphoma, nasal type. Hematol Oncol. 2016;34:61\u20138.","journal-title":"Hematol Oncol"},{"key":"801_CR14","first-page":"1359","volume":"11","author":"YS Nam","year":"2019","unstructured":"Nam YS, Im KI, Kim N, Song Y, Lee JS, Jeon YW, et al. Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK\/T-cell lymphoma. Am J Transl Res. 2019;11:1359\u201373.","journal-title":"Am J Transl Res"},{"key":"801_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1369\/0022155418756849","volume":"66","author":"MW Khan","year":"2018","unstructured":"Khan MW, Ding X, Cotler SJ, Clarke M, Layden BT. Studies on the tissue localization of HKDC1, a putative novel fifth hexokinase, in humans. J Histochem Cytochem. 2018;66:385\u201392.","journal-title":"J Histochem Cytochem"},{"key":"801_CR16","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1242\/jeb.00241","volume":"206","author":"JE Wilson","year":"2003","unstructured":"Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049\u201357.","journal-title":"J Exp Biol"},{"key":"801_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fonc.2018.00104","volume":"8","author":"P Londhe","year":"2018","unstructured":"Londhe P, Yu PY, Ijiri Y, Ladner KJ, Fenger JM, London C, et al. Classical NF-kappaB metabolically reprograms sarcoma cells through regulation of hexokinase 2. Front Oncol. 2018;8:104.","journal-title":"Front Oncol"},{"key":"801_CR18","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1210\/en.2016-1288","volume":"157","author":"AE Ludvik","year":"2016","unstructured":"Ludvik AE, Pusec CM, Priyadarshini M, Angueira AR, Guo C, Lo A, et al. HKDC1 is a novel hexokinase involved in whole-body glucose use. Endocrinology. 2016;157:3452\u201361.","journal-title":"Endocrinology"},{"key":"801_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7069","volume":"6","author":"C Guo","year":"2015","unstructured":"Guo C, Ludvik AE, Arlotto ME, Hayes MG, Armstrong LL, Scholtens DM, et al. Coordinated regulatory variation associated with gestational hyperglycaemia regulates expression of the novel hexokinase HKDC1. Nat Commun. 2015;6:6069.","journal-title":"Nat Commun"},{"key":"801_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.bbrc.2016.05.007","volume":"474","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Huang S, Wang H, Wu J, Chen D, Peng B, et al. High expression of hexokinase domain containing 1 is associated with poor prognosis and aggressive phenotype in hepatocarcinoma. Biochem Biophys Res Commun. 2016;474:673\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"801_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/bioinformatics\/btt606","volume":"30","author":"GH Li","year":"2014","unstructured":"Li GH, Huang JF. Inferring therapeutic targets from heterogeneous data: HKDC1 is a novel potential therapeutic target for cancer. Bioinformatics. 2014;30:748\u201352.","journal-title":"Bioinformatics"},{"key":"801_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2018.07.002","volume":"33","author":"L Fuhr","year":"2018","unstructured":"Fuhr L, El-Athman R, Scrima R, Cela O, Carbone A, Knoop H, et al. The circadian clock regulates metabolic phenotype rewiring via HKDC1 and modulates tumor progression and drug response in colorectal cancer. EBioMedicine. 2018;33:105\u201321.","journal-title":"EBioMedicine"},{"key":"801_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fonc.2019.00290","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Lv Y, Sun Y, Zhang H, Xie W, Zhong L, et al. PGC1beta regulates breast tumor growth and metastasis by SREBP1-mediated HKDC1 expression. Front Oncol. 2019;9:290.","journal-title":"Front Oncol"},{"key":"801_CR24","first-page":"96","volume":"3","author":"DM Irwin","year":"2008","unstructured":"Irwin DM, Tan H. Molecular evolution of the vertebrate hexokinase gene family: identification of a conserved fifth vertebrate hexokinase gene. Comp Biochem Physiol Part D Genom Proteom. 2008;3:96\u2013107.","journal-title":"Comp Biochem Physiol Part D Genom Proteom"},{"key":"801_CR25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/1878-0261.12313","volume":"12","author":"A Shteinfer-Kuzmine","year":"2018","unstructured":"Shteinfer-Kuzmine A, Amsalem Z, Arif T, Zooravlov A, Shoshan-Barmatz V. Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy. Mol Oncol. 2018;12:1077\u2013103.","journal-title":"Mol Oncol"},{"key":"801_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.316","volume":"4","author":"T Prezma","year":"2013","unstructured":"Prezma T, Shteinfer A, Admoni L, Raviv Z, Sela I, Levi I, et al. VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis. 2013;4:e809.","journal-title":"Cell Death Dis"},{"key":"801_CR27","doi-asserted-by":"publisher","first-page":"11392","DOI":"10.1074\/jbc.M110927200","volume":"277","author":"JM Bryson","year":"2002","unstructured":"Bryson JM, Coy PE, Gottlob K, Hay N, Robey RB. Increased hexokinase activity, of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. J Biol Chem. 2002;277:11392\u2013400.","journal-title":"J Biol Chem"},{"key":"801_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.molcel.2004.11.014","volume":"16","author":"N Majewski","year":"2004","unstructured":"Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell. 2004;16:819\u201330.","journal-title":"Mol Cell"},{"key":"801_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0166-6851(99)00164-4","volume":"105","author":"H Kroschewski","year":"2000","unstructured":"Kroschewski H, Ortner S, Steipe B, Scheiner O, Wiedermann G, Duchene M. Differences in substrate specificity and kinetic properties of the recombinant hexokinases HXK1 and HXK2 from Entamoeba histolytica. Mol Biochem Parasitol. 2000;105:71\u201380.","journal-title":"Mol Biochem Parasitol"},{"key":"801_CR30","doi-asserted-by":"publisher","first-page":"94743","DOI":"10.18632\/oncotarget.21889","volume":"8","author":"H Zhang","year":"2017","unstructured":"Zhang H, Li L, Li M, Huang X, Xie W, Xiang W, et al. Combination of betulinic acid and chidamide inhibits acute myeloid leukemia by suppression of the HIF1alpha pathway and generation of reactive oxygen species. Oncotarget. 2017;8:94743\u201358.","journal-title":"Oncotarget"},{"key":"801_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fonc.2018.00265","volume":"8","author":"A El-Sharkawy","year":"2018","unstructured":"El-Sharkawy A, Al Zaidan L, Malki A. Epstein-Barr virus-associated malignancies: roles of viral oncoproteins in carcinogenesis. Front Oncol. 2018;8:265.","journal-title":"Front Oncol"},{"key":"801_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2337\/diabetes.53.2.321","volume":"53","author":"Y Gosmain","year":"2004","unstructured":"Gosmain Y, Lefai E, Ryser S, Roques M, Vidal H. Sterol regulatory element-binding protein-1 mediates the effect of insulin on hexokinase II gene expression in human muscle cells. Diabetes. 2004;53:321\u20139.","journal-title":"Diabetes"},{"key":"801_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1210\/en.2018-00887","volume":"160","author":"CM Pusec","year":"2019","unstructured":"Pusec CM, De Jesus A, Khan MW, Terry AR, Ludvik AE, Xu K, et al. Hepatic HKDC1 expression contributes to liver metabolism. Endocrinology. 2019;160:313\u201330.","journal-title":"Endocrinology"},{"key":"801_CR34","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3109\/10428194.2014.974048","volume":"56","author":"WY Kim","year":"2015","unstructured":"Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim CW, et al. Prognostic implications of CD30 expression in extranodal natural killer\/T-cell lymphoma according to treatment modalities. Leuk Lymphoma. 2015;56:1778\u201386.","journal-title":"Leuk Lymphoma"},{"key":"801_CR35","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2012-06-435024","volume":"120","author":"ZY Wang","year":"2012","unstructured":"Wang ZY, Liu QF, Wang H, Jin J, Wang WH, Wang SL, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK\/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120:2003\u201310.","journal-title":"Blood"},{"key":"801_CR36","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","volume":"125","author":"YW Chen","year":"2015","unstructured":"Chen YW, Guo T, Shen L, Wong KY, Tao Q, Choi WW, et al. Receptor-type tyrosine-protein phosphatase kappa directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma. Blood. 2015;125:1589\u2013600.","journal-title":"Blood"},{"key":"801_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/hon.2360","volume":"35","author":"Y Komabayashi","year":"2017","unstructured":"Komabayashi Y, Kishibe K, Nagato T, Ueda S, Takahara M, Harabuchi Y. Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers for nasal natural killer\/T-cell lymphoma. Hematol Oncol. 2017;35:655\u201363.","journal-title":"Hematol Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0801-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0801-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0801-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:40:00Z","timestamp":1684618800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0801-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0801-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}